Figure 2.

Progressive sarcopenia is associated with a poor response to ICI (immune check-point inhibitor) therapy (A,B) Baseline L3SMI and MMA values are comparable between patients who did or did not respond to ICI therapy at three months. (C,D) Overall longitudinal L3SMI/MMA values between baseline CT (computed tomography) scans and at three months are unaltered. (E) Patients who did not respond to ICI therapy had a significantly lower ∆L3SMI (L3 skeletal muscle index) compared to responders. (F) Patients who did not respond to ICI therapy had a strong trend towards a lower ∆MMA (mean muscle attenuation) compared to responding patients. n.s. non significant, ** p < 0.01.